- Fresenius Medical Care reported fourth-quarter revenue of €5.09 billion, a 1.9% increase compared to the previous year, surpassing the estimated €4.94 billion.
- Operating income for the quarter was €259 million, a decline of 39% compared to the previous year.
- Net income for the quarter decreased to €67 million, down by 64% year-over-year.
- Basic earnings per share (EPS) fell to €0.23 from €0.64 in the same quarter of the previous year.
- For the year 2024, the dividend per share increased to €1.44 from €1.19 in the prior year.
- The company anticipates a low-single digit percentage growth in revenue for 2025 compared to the previous year.
- Operating income is expected to grow by a high-teens to high-twenties percentage rate in 2025 compared to the prior year.
- The FME25 program has accumulated savings of €567 million, with a revised 2025 target of €750 million.
A look at Fresenius Medical Care & Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at the long-term outlook for Fresenius Medical Care, a company offering kidney dialysis services and related products globally, can take cues from the Smartkarma Smart Scores analysis. With high scores in Value and Momentum, along with moderate scores in Dividend, Growth, and Resilience, Fresenius shows promising signs for the future. The company’s strong position in the kidney dialysis market, coupled with its focus on innovation and steady growth, make it an attractive investment option over the long run.
Fresenius Medical Care’s overall outlook, based on the Smartkarma Smart Scores, reflects a solid performance across key factors. With a strong emphasis on value and momentum, supported by consistent dividend payouts and growth potential, the company demonstrates resilience in the face of market challenges. Investors looking for a healthcare company with a diverse range of services and a global presence may find Fresenius Medical Care an appealing choice for their long-term investment portfolios.
### Fresenius Medical Care AG & Co. KGaA offers kidney dialysis services and manufactures and distributes equipment and products used in the treatment of dialysis patients. The Company also offers clinical laboratory testing and diagnostic testing services and provides home infusion, respiratory therapy, ultrasound, and echo-cardiography. Fresenius operates worldwide. ###
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
